Natera (NTRA) executive trades 3,000 shares and receives 10,051 RSUs

Rhea-AI Filing Summary

Natera, Inc. president of clinical diagnostics Solomon Moshkevich reported multiple equity transactions. On March 2, 2026, he exercised stock options for 5,125 shares of common stock at a stated price of $9.5900 per share and received the underlying shares. That same day he sold a total of 3,000 shares of common stock in open‑market transactions in three blocks at weighted average prices of $198.8338, $200.1073, and $200.9679 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 26, 2024, leaving 150,023 shares held directly after the reported sales. On February 27, 2026, he also received a grant of 10,051 restricted stock units, each representing one share of common stock, which vest over four years, with 25% vesting on March 1, 2027 and the rest vesting in 12 equal quarterly installments thereafter.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moshkevich Solomon

(Last) (First) (Middle)

C/O NATERA, INC.

13011 MCCALLEN PASS BUILDING A SUITE 100

(Street)

AUSTIN TX 78753

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Natera, Inc. [ NTRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CLINICALDIAGNOSTICS

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A		10,051(1)	A	(2)	147,898	D
Common Stock	03/02/2026		M		5,125	A	$9.59	153,023	D
Common Stock	03/02/2026		S		931(3)	D	$198.8338(4)	152,092	D
Common Stock	03/02/2026		S		1,594(3)	D	$200.1073(5)	150,498	D
Common Stock	03/02/2026		S		475(3)	D	$200.9679(6)	150,023	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$9.59	03/02/2026		M			5,125	(7)	04/07/2026	Common Stock	5,125	$0	0	D

Explanation of Responses:

1. Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs vest over four years. 25% of the RSUs vest on March 1, 2027 and the remaining RSUs vest in 12 equal quarterly installments thereafter.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.42 to $199.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.6750 to $200.5100 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.72 to $201.16 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The option shares are fully exercisable.

	/s/ Tami Chen, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Natera (NTRA) report for Solomon Moshkevich?

Natera reported that executive Solomon Moshkevich exercised options for 5,125 shares and sold 3,000 common shares in three open‑market trades. He also received a grant of 10,051 restricted stock units that will convert into common stock as they vest over time.

How many Natera (NTRA) shares did the executive sell and at what prices?

The executive sold a total of 3,000 Natera common shares on March 2, 2026 in three blocks. Weighted average sale prices were $198.8338, $200.1073, and $200.9679 per share, with each set of trades executed within narrow price ranges disclosed in the footnotes.

What stock option exercise did Natera (NTRA) disclose for its executive?

Natera disclosed that Solomon Moshkevich exercised stock options for 5,125 shares of common stock on March 2, 2026 at a stated exercise price of $9.5900 per share. Following the related transactions, his directly held common stock position was updated in the filing.

What restricted stock units were granted to the Natera (NTRA) executive?

On February 27, 2026, the executive received 10,051 restricted stock units, each representing one share of Natera common stock. These RSUs vest over four years, with 25% vesting on March 1, 2027 and the remainder in 12 equal quarterly installments thereafter.

Was the Natera (NTRA) insider sale under a Rule 10b5-1 trading plan?

Yes. The filing states that the reported share sales were executed under a Rule 10b5‑1 trading plan adopted by the reporting person on November 26, 2024. Such plans allow pre‑arranged trading schedules intended to separate personal trading decisions from day‑to‑day market conditions.

How many Natera (NTRA) shares does the executive hold after these transactions?

After the reported March 2, 2026 sales, the executive directly held 150,023 shares of Natera common stock. This figure reflects the updated balance immediately following the option exercise, receipt of underlying shares, and subsequent open‑market sales disclosed in the Form 4 filing.